UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Current concepts for the management of head and neck cancer: Chemotherapy

Oral oncology, 2009-04, Vol.45 (4), p.409-415

2009

Volltextzugriff (PDF)

Recurrent head and neck cancer: current treatment and future prospects

Expert review of anticancer therapy, 2008-03, Vol.8 (3), p.375-391

2008

Volltextzugriff (PDF)

Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck

Anticancer research, 2009-12, Vol.29 (12), p.5137-5142

2009

Volltextzugriff (PDF)

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

BMC cancer, 2009-08, Vol.9 (1), p.273-273, Article 273

2009

Volltextzugriff (PDF)

Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited?

Cancer letters, 2007-10, Vol.256 (2), p.166-177

2007

Volltextzugriff (PDF)

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma

Radiotherapy and oncology, 2012-11, Vol.105 (2), p.238-240

2012

Volltextzugriff (PDF)

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

Cancer chemotherapy and pharmacology, 2009-07, Vol.64 (2), p.233-241

2009

Volltextzugriff (PDF)

Targeted therapies in head and neck cancer

Targeted oncology, 2007-04, Vol.2 (2), p.73-88

2007

Volltextzugriff (PDF)

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6076-6076

2016

Volltextzugriff (PDF)

ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6021-6021

2016

Volltextzugriff (PDF)

Current concepts for the management of head and neck cancer: Chemotherapy: Oral Cancer Management. Pitfalls and Solutions

Oral oncology, 2009, Vol.45 (4-5), p.409-415

2009

Volltextzugriff (PDF)

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data

Annals of oncology, 2007-11, Vol.18 (11), p.1856-1860

2007

Volltextzugriff (PDF)

Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2061-2061

2013

Volltextzugriff (PDF)

Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.6002-6002

2013

Volltextzugriff (PDF)

Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus

The journal of clinical endocrinology and metabolism, 2018-09, Vol.103 (9), p.3144-3154

2018

Volltextzugriff (PDF)

Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus

The journal of clinical endocrinology and metabolism, 2018-09, Vol.103 (9), p.3144-3154

2018

Volltextzugriff (PDF)

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms

Frontiers in oncology, 2020-06, Vol.10, p.1020-1020

2020

Volltextzugriff (PDF)

Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

PloS one, 2021-06, Vol.16 (6), p.e0252646-e0252646

2021

Volltextzugriff (PDF)

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-08, Vol.18 (8), p.1146-1156

2016

Volltextzugriff (PDF)

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study

European journal of nuclear medicine and molecular imaging, 2020-05, Vol.47 (5), p.1075-1082

2020

Volltextzugriff (PDF)

Gemcitabine‐Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta‐Analysis

The oncologist (Dayton, Ohio), 2016-01, Vol.21 (1), p.59-71

2016

Volltextzugriff (PDF)

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Cancer, 2016-12, Vol.122 (24), p.3803-3811

2016

Volltextzugriff (PDF)

Health related quality of life in older patients with solid tumors and prognostic factors for decline

Journal of geriatric oncology, 2019-11, Vol.10 (6), p.895-903

2019

Volltextzugriff (PDF)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

International journal of molecular sciences, 2017-05, Vol.18 (5), p.995

2017

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Bücher
(1)

Sprache

Englisch
(32)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(23)
Oncology
(21)
Humans
(19)
Male
(12)
Head And Neck Cancer
(11)
Female
(10)
Middle Aged
(9)
Adult
(8)
Aged
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Chemotherapy
(8)
Cisplatin - Administration & Dosage
(7)
Treatment Outcome
(7)
Tumors
(7)
Carcinoma, Squamous Cell - Drug Therapy
(6)
Head And Neck Neoplasms - Drug Therapy
(6)
Head And Neck Neoplasms - Pathology
(6)
Cancer
(5)
Carcinoma, Squamous Cell - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current concepts for the management of head and neck cancer: Chemotherapy

Recurrent head and neck cancer: current treatment and future prospects

Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

Neoadjuvant chemotherapy in head and neck cancer: Should it be revisited?

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

Targeted therapies in head and neck cancer

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial

ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT)

Current concepts for the management of head and neck cancer: Chemotherapy: Oral Cancer Management. Pitfalls and Solutions

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data

Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression

Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study

Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus

Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms

Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study

Gemcitabine‐Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta‐Analysis

Long-term health-related quality of life in head and neck cancer survivors: A large multinational study

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Health related quality of life in older patients with solid tumors and prognostic factors for decline

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Suchergebnisse filtern